Thec rosstalk between coagulation and inflammation and the propensity formicrothromboembolic disease during sepsis calls fora nticoagulant measures to preventt issueh ypoxygenation and to attenuate organ damage and dysfunction. Onlyone anticoagulant, recombinant human activated protein C(aPC,drotrecogin-α )has aprovensurvival benefit when used as an adjunctivetherapy forhuman sepsis,partlybecause of its anti-inflammatorye ffect. However, heparin (-likec ompounds) maye xert similar beneficial anti-inflammatory actions as aPC,ins pite of the relativelyn arrowt herapeutic window fora nticoagulation.
Introduction
Sepsis,the host response to severe microbialinfection, is an important health problem, being the leading cause of death in the intensive care unit. Theinflammatoryresponsetoinfection and tissue injuryischaracterizedbyalocaland systemic release of pro-and anti-inflammatoryfactorsand changes in the microcirculation, impairing vascularb arrier function resulting in extravasation of plasma proteins and leukocytes. An essential early step in the inflammatoryreaction is the migration of neutrophils to the site of infection followedbyadherencetothe vascularendothelium in ordertopermeatethe vesselwalland penetrate the tissues. In this neutrophil-endothelium interface, activation of coagulation mayplayanimportant role.
Activation of an inflammatoryresponseduring infection and sepsis mayr esulti napro-coagulant state (1) (2) (3) (4) .L ipopolysaccharide (LPS) or endotoxin decreases anticoagulant heparan sulphate and other glycosaminoglycans (GAGs)inendothelium and increases tissue factor (TF)production and releasebymacrophages (4, 5) . Theresultant activation of coagulation, independentlyfollowedb yinhibition of fibrinolysis, mayresultindisseminatedi ntravascularc oagulation (DIC), microvascularo bstruction, and therebyorgan dysfunction and damage, whichis characteristic forsepsis. Thelatterisaccompaniedbyconsumption and depletion of natural anticoagulants such as antithrombin (AT), protein C(PC) and tissue factor pathway inhibitor (TFPI), and releaseofplasminogenactivator inhibitor (PAI-1) inhibiting fibrinolysis (1, 4, (6) (7) (8) (9) . Hence,repletion of anticoagulants could reverse the imbalanceofcoagulation to fibrinolysis in sepsis (4) . Conversely, activation of coagulation haspro-inflammatory effectsvia the TF/factor VII complex,thrombin and fibrin, resulting in releaseo fc ytokines by leukocytesa nd endothelium, amongo thers, while factor Xa ctivation mayh avel essp ro-inflammatory effects (4, (10) (11) (12) (13) . Clearly, the crosstalk between coagulation and inflammation opens neww aysf or treatment of sepsis (4, 12) .
Recently, three major,phase IIItrials on the three naturally occurring anticoagulants, i.e. activatedprotein C(aPC) or drotrecogin-α (recombinanth uman aPC) (PROWESS-trial) (14) , antithrombin (KyberSept-trial) (15) (16) (17) and tissue factor pathwayinhibitor (OPTIMIST-trial) (18) have beenperformed. The PROWESS-trialwas the onlytrial so fartodemonstrate astatistically significant reduction of the (absolute)m ortality rate by 6.1%. However, in allthreetrials,low-dose prophylacticheparin hasbeen used as co-treatment, and study results suggested that the drug intervention wasm ost effective and safe,w ith less bleeding complications,inthe group not receiving heparin (14, 15, (17) (18) (19) .
Therefore, we reviewed the effectso fh eparin (-likec ompounds) beyond coagulation, during sepsis and shock. Fort his narrative review,Englishpapershavebeen included, as foundin aMedline search.Wewill addressthe propertiesofheparin as a chemical compound, anticoagulant and anti-inflammatory drugs, both in vitro as well as in animalexperiments and human studies, during sepsis and shock, to enforcethe idea that arandomized trialo fl ow/prophylactic or even therapeutic doses of heparinisneeded,inthe treatment of sepsis and shock in man.
Heparin as an anti-coagulant andimmunemodulating agent
Heparin is anaturally occurring GAG, produced by mast cells in intestineso rl ung, basophils in blood,a nd endothelial cells (20) (21) (22) .H eparin consists of alternating chains of uronic acid and glucosamine, sulphated to av arying degree. Thep harmaceutical drug is extracted fromporcine or bovine mucosa;unfractionated heparin weighing13,000 -15,000 Dalton (Da) and fractionated or low-molecular-weight heparin3,000 -5,000 Da (23, 24) . Heparin exerts anti-coagulant propertiesbybindingto AT and heparinc ofactor II (21, 24) . The bond to AT,w hich requiresaunique pentasaccharide sequence,r esults in ac onformational change, potentiating the ability of AT to inactivate the coagulation factorsIXa, Xa, XIa and XIIa (25) . Followinginactivation of factor Xa, prothrombinc annot be converted to thrombin,therebyinhibiting conversion of fibrinogen to fibrin and clotting of blood. Moreover,heparin directly inhibits thrombin, buts incethis requiresaminimum chainl ength of 18 saccharidestosimultaneously bind thrombin and AT,itisexclusive to unfractionated heparin.F ractionated heparinsa nd pentasaccharidesexert morespecific anti-factor Xactivity thanunfractionatedheparin (21, 26) . Inhibition of thrombin-inducedfeedback activation of coagulation factorsVand VIII contributesto the anticoagulant activity of heparin (27) . Endothelial release of TFPIand reducede xpression of TF and PA I-1 mayalso playa role ( 28) . Heparin reverses the pro-coagulant propertieso f stimulatedendothelial cells (29) .
The anticoagulant properties of heparin (-likec ompounds) during endotoxaemia and sepsis mayevensurpass drotrecogin-α 's (7-9, 13,30, 31) . Heparin as treatment for activatedcoagulation during sepsis, however, might impair interaction of AT withGAGsinendothelium (17, (32) (33) (34) (35) , and might deplete the endothelium and blood of TFPIi ns pite of increased synthesis (28, 35) . These phenomena maypartlye xplain the lackofsurvivalb enefit of AT /TFPI in the heparin-cotreated patients in largemulticenter trials (15, 17, 18) . Thrombin pre-treatment of LPS-induced shock in animals protectedagainst coagulation activation and mortality in animals, potentiallyb ecauseo fe nhancement of aPC, since thrombin binds to thrombomodulin therebya ctivating protein C ( 36) . Heparin (-likec ompounds) synergize with the favourablee ffectso fa PC on neutrophil-endothelialinteractions (37),but mayantagonize aPC by promoting the aPC inhibitor (38) or augment aPC in anti-coagulation by activating aPC-induced inhibition of factor V, thus aggravating the risk of bleeding (39) .This mayexplain the seeminglylessfavourableeffectsofdrotrecogin-α in heparin-cotreated sepsis patients in the PROWESStrial (14) . 
Anti-inflammatoryactions
Heparin mayplayarole in inhibiting the production andrelease of pro-inflammatory factors ( Fig. 1) (20) . Thrombin has pro-inflammatoryp ropertiesa nd increases endothelial permeability andendothelinproduction (11) . AT andaPC inhibitnuclear factor(NF) κ B, atranscription factorresponsible for gene expression of pro-inflammatory factors in monocytesa nd endothelium (33) (34) (35) 40) . Heparinmightthus modulate anti-inflammatoryeffects of AT or aPC (35, 40) . The anti-inflammatoryaction of heparinmay relate to inhibition of thrombin formation, even though chemicallymodifiedheparin-likecompounds without anticoagulant action mayhavepreserved anti-inflammatoryproperties (11, 24, (41) (42) (43) (44) . Both (un)fractionatedand modified,non-anticoagulant heparininhibitthe activation of NFκ B, the pro-inflammatory responses after ischaemia/reperfusion, andattenuate endothelial dysfunction by enhancing nitrico xide (NO)a nd prostacyclin (44) (45) (46) (47) . Similarly,( non-anticoagulant) heparini mproves endothelial function andv ascular reactivityd uring hyperdynamic sepsis (41) . Although not demonstrableinwhole blood or during humane ndotoxaemia, (un)fractionatedh eparin (sulphate)i nhibitedgeneexpression, production andreleaseofpro-inflammatorycytokinesbyLPS-stimulated monocytes and other cells,mediatedbythrombin andNF κ Bactivation in vitro (9, 11, (48) (49) (50) (51) (52) .
In vasculara dherence, migration and activation of leukocytes, heparinsulphate mayplayamodulating role.Heparin inhibits the chemotaxisofnormal human neutrophils (53, 54) . The effects seemed to relate primarilyt oi nhibition of C5a, ap ositively charged peptide thatmay be neutralizedbythe negatively charged heparin. In vivo and in vitro ,(non-anticoagulant) heparinderivatesprevented in partcomplement activation and subsequent neutrophil activation (55,5 6) . Furthermore,h eparin is the most potent enhancer of allnaturally occurring GAGs, of the inhibitoryc apacity of C1-inhibitor (57,5 8) . Heparan sulphate maybind and present cytokines/chemokines,enhancing IL-8-inducedchemotaxis (59) .Bycompeting with heparin sulphate in binding these cytokines/chemokines,i ntravascularh eparin could partly antagonize these eventsatthe neutrophil-endotheliali nterface (46, (59) (60) (61) .N eutrophil-derivedh eparin binding protein mayinteractwith endothelialGAGs, altering the cytoskeleton and increasing permeability and neutrophil transmigration (59, 62) . GAGs and heparins promote endothelial barrier function (63) . Heparan sulphate in the endothelium also synergizes with adhesion molecules in neutrophil adherence, chemotaxis and endotheliali nteractions (60, 61, 64, 65) . Conversely, heparin in the blood is able to bind to leukocytes by L-selectin, and to endothelium by glycosylation-dependent cell ad- hesion molecule-1 (GlyCAM-1) and P-selectin (9, 64-67). Heparinmay downregulate endothelial intercellular adhesion molecule-1( ICAM-1) and L-selectin expression more than that of E-selectin, even in ahuman endotoxaemia model (9, 43, (68) (69) (70) (54) . Thea nti-inflammatoryr ole of heparin maya lso apply to extracorporeal circuits. Reductions of circulating pro-inflammatorycytokines were found in patients on heparin-coated cardiopulmonary bypass (CPB), in partmediated by inhibition of complement activation (76) (77) (78) ; in rabbits, formation of TNF-α was completelyp revented by prior heparin coating (79) .C omplement activation is inhibitedbyheparin and heparincoating of circuits during CPB,asmeasured by reduced levels of C5 and C3 split products and terminalcomplement complexes, and heparin (coated circuits) mayt herebyi mprovep ostoperative recovery (55,7 8, 80-84) . Expression of adhesion and activation molecules on neutrophils and macrophages and releaseo fe lastase were reduced when heparin-coated versusuncoated circuits were used,a ssociatedi np artw ith reduced complementa ctivation (80) (81) (82) (83) 85) . These effects have mostlybeen shown at very high doses of heparin.
Pro-inflammatoryeffectsofheparin (-likecompounds) have also been described,inpartconflicting with above findings, and the discrepancym ay relatet om odels, prior stimuli,d oses and types of administration. High-dose heparin mayd ecreasee ndothelial NO production and promote cell adhesion and (platelet) aggregation (86). ProductionofTNF-α ,IL-1β and TF by isolatedm onocytes and whole blood,m ay be enhancedw hen (fractionated) heparin is added (49, 87, 88) . Addition of heparin to whole blood challenged with LPS mayresultinanincreased IL-8production (89)and maypromotestimulatedmacrophages to produce cytokines (90) .GAGsmay associate with extracellularsuperoxide dismutase (SOD) and therebyhelptoneutralize neutrophil-derived reactiveoxygen species, and heparin in blood maydisplace protectiveSOD from endothelium (91, 92) . Heparin mayupregulate neutrophil CD11b and enhance IL-8release in vitro (68) . Other reportssuggest apro-inflammatory genetic response in leukocytes evoked by heparin coating of circuits (93) .Inaprospectivetrial on 200patients on CPB with or without heparin-coatedcircuits, arise in cytokinelevelsoccurred in both groups, without significant differences (94) .
Heparin treatment in sepsis animalmodels
Filkins et al.were the first to studythe protective effect of heparininLPS-induced shock; rats receiving heparinbefore or after injection of Salmonella and E. coli LPShad lowermortality than untreatedrats (95) .
In experimental fecalperitonitis,heparin ameliorated peritoneal fibrin deposition and favorably affected survivaltime,blood pressure, leukocyte countsa nd lung injury ( 96, 97) , and improvedthe haematologic abnormalities compatible with DICina sepsis modelinrats (98) . In rodent LPS and sepsis models, treatment by heparin (-likecompounds) wasabletodiminish coagulation activation, (renal)fibrin deposits, microthrombi in lung and livera nd to improve hepatocellular function and survival (99) (100) (101) (102) (103) . Inhalation of heparina ttenuatesa cutel ung injury (ALI) followings mokei nhalation and bacterial pneumonia in sheep, while intravenous heparinm ay be less helpful in sheep and ratsa lthough attenuating ALIi ne ndotoxaemic pigs (104) (105) (106) (107) .In-vitro heparin mayenhancesurfactant protein gene expression in pneumocytes (108) .I nar ecent,s ustained and ovine LPS-induced shockmodel (109),unfractionated heparin, hirudin or saline wasgiven. Sheep in the heparingroupexhibited high survivalr ates because of less deterioration of cardiopulmonary function.S inceb oth heparin and hirudin completely prevented the earlyLPS-induced decreaseinplasma fibrinogen, the non-anticoagulant propertiesofheparin might have beenresponsible forthe survivalbenefit. Furthermore,anticoagulation, for instancewith heparin, mayhardly enhance the clearance of LPS ( 100, 110, 111) , so that the favorable effect of heparini n some of the above studiesmay not relate to an altered host defense by heparin. Non-anticoagulant heparin appeared to maintain vasculare ndothelial cell function during sepsis or after haemorrhage in rats (41, 42) . In sheepreceiving acontinuous infusion of E. coli LPS,heparin treatment increased cardiac output and decreased pulmonary shunting and systemic vascularresistanceindex, as comparedtoplacebo-treated animals (112) .
In contrast, Corriganetal. did not observe asurvivalbenefit by heparin treatment in rabbits intraperitoneallyi njected with (Gram-negative) P. multocida,t hough fibrinogen consumption wasdiminished (113) . In endotoxaemic hamsters (32), (un)fractionatedheparin did not affect or attenuate the AT-mediated inhibitionofleukocyteadhesion and capillaryperfusion failure. In rabbitendotoxaemia, however, fractionated heparin,was only effectiveifcombined with AT (6).
Takent ogether,t he animal experimental literaturei sg enerally in favorofabeneficialeffect of heparin(-likecompounds) while modesofaction maydependonsepsis models, drugs,timing, dosing and routes of administration. We performed ametaanalysis (ComprehensiveM eta-analysis version 2, www.metaanalysis.com, NIHU SA,l asta ccessedA pril 2007) of animal sepsis survivals tudiesm entioneda bove and founda no verall benefit of treatment by heparin (Fig. 2) . Togetherwith some preliminary human data,the analysis could underpinafuture prospective randomized clinical trial.
Heparin foradjunctivetreatment of human sepsis andshock
Low-molecular-weight heparins playa ni mportant rolei nt he prophylaxis of thromboembolic disease in the criticallyi ll patient with sepsis and shock, whicha re major risk factorsf or thromboembolic disease, although fatalp ulmonarye mbolism maynot be prevented in patients with infections (114) (115) (116) .
When comparing the heparin-treated and untreated patients in the placebo arms of the PROWESS, KyberSept and OPTI-MIST trials, the former seemtohavea(non-significant) survival advantage (117,1 18) . In the KyberSept and OPTIMIST trials, patients treatedw ith heparina lone even had al ower mortality thant hose treatedw ith the studyd rugo rp lacebo (119) . After pooling placebo datafrom all three trials, the oddsratio for death of the patients whoreceivedheparin as compared to thosewho did not, was0 .65 (P<0.00001) (120) .T he number-needed-totreat (NNT) with heparin to prevent one death, basedo nt hat analysis, would be 10, whichmay be similar to or even lowerthan the NNT for aPC (120) .However,these observations are the results of post-hoc analyses,r endering it hard to draw firm conclusions becauseofunintended pitfalls (19, 121) . Furthermore, heparin wasadministeredonclinical grounds so that aselection biasmay have occurred.
The XPRESS study (LillyC ritical Care Europe: XIGRIS R summaryo ff indings in the XPRESS trial, submittedm anuscript),designedtodemonstrate thatinadult patients with severe sepsisreceiving drotrecogin-α ,concomitant treatment with subcutaneous prophylactic heparin wasequivalent to treatment with placebo (determinedby28-dayall-causemortality), showedthat the group concomitantlytreated with heparinhad atrend towards alower mortality rate, therebysuggesting abeneficialeffect of heparinitself,insteadofbeing an unsafe combination with aPC. Furthermore heparin seemed to exertprotective effectsinterms of thrombotic events, suggesting synergistic actions of the agents (122) . Theincidence of ischemic strokewas significantly higher in the group treatedwith drotrecogin-α alone, and venous thromboembolic eventsoccurred moreoften, althoughnot statisticallysignificant.The number of serious bleeding eventsand clinicallyd iagnosedh eparin-induced thrombocytopenia (HIT) wasequal in both groups (LillyCritical Care Europe: XIGRIS  summaryo ff indings in the XPRESS trial, submittedm anuscript).Uncontrolled observations also suggest abeneficialeffect of heparin in combination with protein Cinmeningococcal sepsis (123) ,but one uncontrolled trial of heparin in human sepsis, suggests no survivalbenefit in spite of amelioration of DIC (30) .
Conclusion
Apartfrom potent anticoagulant propertiesheparin also hasantiinflammatoryproperties. Althoughthe effects of heparin on survivalinanimal endotoxaemia or sepsis seemtoargue in favorof heparin administration, as demonstrated by the meta-analysis in this review,t hese effects have,u ntil now, not beens tudiedi n human endotoxaemia or sepsis by means of alarge randomised clinical trial. Post-hoca nalyses of the threem ajor sepsis trials and the XPRESS studysuggest that low-dose heparin might have favorable effectso ns urvival. Ar andomisedc linical trial, the (low-dose, continuouslyi nfused, unfractionated) heparin for treatment of sepsis -HETRASE-study is underway to evaluate this concept further (124) .This could be supplementedbyatrial of prophylacticv ersus therapeutic doses of low-molecularweight heparins,but the dose and route of administration should be carefullyc hosen since subcutaneouslya dministeredc ompounds mayn ot be absorbed well in patients on vasopressors, and bleeding risks should not be severelyincreased (125) .Furthermore,side effectsofheparin therapy, likebleeding,HIT and allergicreactions,might limit the setup of largetrials.Upuntil now, the treatment with aPC/drotrecogin-α remains the only anticoagulant therapywith proven efficacyinhuman sepsis and shock (14) ,eventhough the benefitmay be mainlyconferred by direct anti-inflammatoryrather thanbyanticoagulant properties (14) .
